Sam Chun Dang Pharm. Co. Ltd. Report issue

For profit Phase 3
Founded: Hwaseong-si Korea, Republic of (1943)

Organization Overview

First Clinical Trial
2020
NCT04480463
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sam Chun Dang Pharm. Co. Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

aflibercept (zaltrap) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 3)

Wet Macular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1